VRTX vs GILD
VRTX and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $124.16B | $166.82B |
| P/E (TTM) | 29.0 | 18.3 |
| P/B | 6.41 | 7.09 |
| P/S | 10.4x | 5.7x |
| Dividend yield | — | 2.40% |
| Revenue | $12.22B(TTM) | $29.74B(TTM) |
| Revenue growth (YoY) | 8.9% | 2.4% |
| Net income | $4.34B(TTM) | $9.22B(TTM) |
| Earnings growth (YoY) | 838.1% | 1672.9% |
| EPS, diluted | $16.85(TTM) | $7.35(TTM) |
| EBIT margin | 34.8% | 34.0% |
| ROE | 20.4% | 36.2% |
| ROIC | 25.4% | 21.6% |
| 1y total return | +4.6% | +20.4% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: VRTX vs GILD
| 지표 | VRTX | GILD |
|---|---|---|
| 최종 가치 | $62.1K | $20.8K |
| 총수익률 | +521.3% | +108.3% |
| CAGR | +19.3% | +7.4% |
| 변동성 | 33.0% | 25.7% |
| 샤프 | 0.58 | 0.25 |
| 소르티노 | 0.86 | 0.37 |
| 최대 낙폭 | -41.6% | -36.0% |
공통 거래일 2600일 기준, 2016-03-28 → 2026-07-29 · 무위험수익률 3.9% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)